Abstract
The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Current Drug Targets
Title: Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models
Volume: 9 Issue: 3
Author(s): Michael E. Rosenfeld, Michelle M. Averill, Brian J. Bennett and Stephen M. Schwartz
Affiliation:
Abstract: The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Export Options
About this article
Cite this article as:
Rosenfeld E. Michael, Averill M. Michelle, Bennett J. Brian and Schwartz M. Stephen, Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models, Current Drug Targets 2008; 9(3) . https://dx.doi.org/10.2174/138945008783755575
DOI https://dx.doi.org/10.2174/138945008783755575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Acute Kidney Injury after Complex Endovascular Aneurysm Repair
Current Pharmaceutical Design Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Efficacy of HGF Gene Transfer for Various Nervous Injuries and Disorders
Central Nervous System Agents in Medicinal Chemistry Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders